Rx (Prescription Medicine)
USD $ 120.00
Bevacizab 100mg 注射液是一种靶向治疗，用于多种癌症的治疗。其活性成分为 Bevacizumab，是一种重组人源化单克隆抗体，通过抑制血管内皮生长因子（VEGF）起作用。VEGF 是一种促进新血管生长的蛋白质，而新血管是肿瘤生长和转移所必需的。通过阻断 VEGF，Bevacizab 有助于减缓或停止肿瘤的生长，并可防止转移。它通常与化疗联合使用，用于治疗如转移性结直肠癌、非小细胞肺癌、胶质母细胞瘤和转移性肾细胞癌等情况。具体的用药剂量和给药方案由主治医生根据癌症的类型、分期以及患者的整体健康状况确定。常见的副作用可能包括高血压、尿蛋白、鼻出血和疲劳。较少见但严重的副作用可能涉及出血事件、伤口愈合并发症以及肠道穿孔。Bevacizab 100mg 注射液应储存在室温、避光处，且不可冷冻。使用本药时请务必严格遵循医生的指示。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Strength | |
| Brand Name | |
| Molecule | |
| Strength | 100 Mg |
| Medicine Form | Injection |
| Pack Quantity | 1 Vial |
| Packaging Type | Vial |
| Medicine Type | Branded |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
其他品牌的 Bevacizumab 100 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
